Abstract: In an embodiment, a polyurethane comprises the residues of i. an aliphatic diisocyanate, ii. an aliphatic diol comprising a poly(ethylene oxide) moiety, iii. an aliphatic diol comprising a polycarbonate moiety, and iv. a chain extender, wherein the polyurethane has a melting temperature of 140° C. or less and has a weight average molecular weight of from 100,000 to 500,000 g/mol. In an embodiment, the polyurethane is substantially devoid of catalyst. In an embodiment, the polyurethane is formed by reactive extrusion. In an embodiment, a medical device comprises the polyurethane and a bioactive agent. The medical devices, methods, and polyurethanes may exhibit benefits in end-product biostability, drug release profile, health and safety, and processing speed or reproducibility.

Abstract: In an embodiment, a polyurethane comprises the residues of i. an aliphatic diisocyanate, ii. an aliphatic diol comprising a poly(ethylene oxide) moiety, iii. an aliphatic diol comprising a polycarbonate moiety, and iv. a chain extender, wherein the polyurethane has a melting temperature of 140° C. or less and has a weight average molecular weight of from 100,000 to 500,000 g/mol. In an embodiment, the polyurethane is substantially devoid of catalyst. In an embodiment, the polyurethane is formed by reactive extrusion. In an embodiment, a medical device comprises the polyurethane and a bioactive agent. The medical devices, methods, and polyurethanes may exhibit benefits in end-product biostability, drug release profile, health and safety, and processing speed or reproducibility.

Abstract: In an embodiment, a polyurethane comprises the residues of i. an aliphatic diisocyanate, ii. an aliphatic diol comprising a poly(ethylene oxide) moiety, iii. an aliphatic diol comprising a polycarbonate moiety, and iv. a chain extender, wherein the polyurethane has a melting temperature of 140° C. or less and has a weight average molecular weight of from 100,000 to 500,000 g/mol. In an embodiment, the polyurethane is substantially devoid of catalyst. In an embodiment, the polyurethane is formed by reactive extrusion. In an embodiment, a medical device comprises the polyurethane and a bioactive agent. The medical devices, methods, and polyurethanes may exhibit benefits in end-product biostability, drug release profile, health and safety, and processing speed or reproducibility.

Abstract: Disclosed herein are compositions and kits of materials for forming a component of a rigid gas permeable lens. An exemplary composition comprises a hydroxyl terminated polyurethane pre-polymer having an average of more than one hydroxyl group per molecule comprising: i) the residue of an aliphatic diisocyanate, a block of comprising polysiloxane and a block comprising hydrophobic poly(alkylene oxide), or ii) the residue of an aliphatic diisocyanate, a block comprising fluoroalkyl or fluoroalkyl ether, and a block of comprising hydrophobic poly(alkylene oxide). The composition further comprises a free aliphatic diisocyanate and a monomeric polyol, or a propoxylate thereof. The average number of hydroxyl groups of the hydroxyl terminated pre-polymer plus the average number of hydroxyl groups of the monomeric polyol, or a propoxylate thereof is equal to from 4.5 to 5.5. Kits of materials comprising elements that when combined form the composition are also disclosed.

Abstract: Disclosed herein are compositions and kits of materials for forming a component of a rigid gas permeable lens. An exemplary composition comprises a) an isocyanate terminated pre-polymer having an average of more than one isocyanate group per molecule and that is the reaction product of at least: i) an aliphatic diisocyanate, and ii) a diol component comprising a siloxane diol, a fluorinated diol, and/or a hydrophobic poly(alkylene oxide) diol, b) a hydrophobic poly(alkylene oxide) diol, and c) a monomeric polyol or a propoxylate thereof. The average number of isocyanate groups of the isocyanate terminated pre-polymer plus the average number of hydroxyl groups of the monomeric polyol, or a propoxylate thereof is equal to from 4.5 to 5.5. Kits of materials comprising elements that when combined form the composition are also disclosed. Further disclosed are articles and ocular devices comprising components formed from the compositions or kits.

Abstract: The present disclosure relates to microparticles or nanoparticles comprising a polyesteramide (PEA) having a chemical formula described by structural formula (IV), wherein m+p varies from 0.9-0.1 and q varies from 0.1 to 0.9; m+p+q=1 whereby m or p could be 0; n is about 5 to about 300; (pref.

Abstract: A method for activating silicone rubber surfaces comprising steps of: i) swelling at least the surface of the silicone rubber matrix with a silicone rubber swelling solvent; ii) treating the silicone rubber matrix during or after the swelling with a solution comprising at least a reactive silane, the reactive silane comprising: a) at least one Si—C bond and; b) at least one hydrolytically labile bond linked to at least one of the Si atoms present in the reactive silane and; c) at least one functional group F1 connected via a Si—C bond to the same or an other Si atom present in the reactive silane, the functional group comprising electrophilic and/or nucleophilic moieties, and/or at least one functional group F2 connected via a Si—C bond to the same or an other Si atom present in the reactive silane comprising moieties which become electrophilic or nucleophilic moieties by a mechanism selected from the group consisting of ring opening of a cyclic structure, hydrolysis, displacement or by a migration reactio

Abstract: A method for activating silicone rubber surfaces comprising steps of: i) swelling at least the surface of the silicone rubber matrix with a silicone rubber swelling solvent; ii) treating the silicone rubber matrix during or after the swelling with a solution comprising at least a reactive silane, the reactive silane comprising: a) at least one Si—C bond and; b) at least one hydrolytically labile bond linked to at least one of the Si atoms present in the reactive silane and; c) at least one functional group F1 connected via a Si—C bond to the same or an other Si atom present in the reactive silane, the functional group comprising electrophilic and/or nucleophilic moieties, and/or at least one functional group F2 connected via a Si—C bond to the same or an other Si atom present in the reactive silane comprising moieties which become electrophilic or nucleophilic moieties by a mechanism selected from the group consisting of ring opening of a cyclic structure, hydrolysis, displacement or by a migration reaction;

Abstract: The invention relates to a coating comprising a biodegradable polymer comprising at least two different functional groups pendant to the polymer backbone, which functional groups are selected from the group of carboxyl-, amine, hydroxyl, ester, amide-, thiol- or thioester groups. The two different functional groups comprise at least an unprotected hydrophilic functional group chosen from a carboxyl-, amine, thiol or hydroxyl group and at least a protected hydrophobic functional group chosen from an ester, amide- or thioester group. The invention further relates to an implantable device comprising the coating composition. The implantable device is includes cardiac pacemakers and defibrillators; leads and electrodes for the preceding, organ stimulators such as nerve, bladder, sphincter and diaphragm stimulators, prostheses, rods, vascular grafts, self-expandable stents, balloon-expandable stents, stent-grafts, grafts, catheters, artificial heart valves and cerebrospinal fluid shunts.

Abstract: The present invention relates to a process for the manufacturing of a multilayer construct comprising layering at least one drug loaded film from which each film comprises a polymer and at least a drug manufactured by the steps of dissolving the polymer in an organic solvent, mixing the dissolved polymer with the drug, laminating the mixture between at least two polymeric sheets, whereby at least one sheet is permeable to the organic solvent, removing the sheets to provide the drug loaded film, layering the drug loaded film and fusing the drug loaded films into a multilayer construct. The present invention also relates to the multilayer construct obtainable by the process according to the present invention and to the use of the multilayer construct in ophthalmology, cardiovascular, pain management, musculoskeletal, cancer treatment or in vaccine delivery.

Abstract: Process for the manufacturing of a drug delivery system based on a polymer comprising dispersed bioactive agent via the following process steps: (a) dissolving a polymer in an organic solvent (b) mixing the dissolved polymer with the bioactive agent (c) laminating the mixture between two polymer sheets, whereby at least one of the sheets is permeable to the organic solvent, to provide a film whereby the film can be further processed into the drug delivery system. The drug delivery system is suitable for implantation or injection and comprises fibres, rods, discs, coatings, tubes, films or rolled films.

Abstract: The present invention relates to micro- or nanoparticles comprising a polyesteramide (PEA) having a chemical formula described by structural formula (IV), Formula (IV) wherein —m+p varies from 0.9-0.1 and q varies from 0.1 to 0.9 —m+p+q=1 whereby m or p could be 0-n is about 5 to about 300; (pref 50-200) —R1 is independently selected from the group consisting of (C2-C20) alkylene, (C2-C20) alkenylene, —(R9—CO—O—R10—O—CO—R9)—, —CHR11—O—CO—R12—COOCR11— and combinations thereof; —R3 and R4 in a single backbone unit m or p, respectively, are independently selected from the group consisting of hydrogen, (C1C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl, (C1-C6)alkyl, —(CH2)SH, —(CH2)2S(CH3), —CH2OH, —CH(OH)CH3, —(CH2)4NH3+, —(CH2)3NHC(?NH2+)NH2, —CH2COOH, —(CH2)COOH, —CH2—CO—NH2, —CH2CH2—CO—NH2, —CH2CH2COOH, CH3—CH2—CH(CH3)—, (CH3)2—CH—CH2—, H2N—(CH2)4—, Ph-CH2—, CH?C—CH2—, HO-p-Ph-CH2—, (CH3)2—CH—, Ph-NH—, NH—(CH2)3—C—, NH—CH?N—CH?C—CH2—.

Abstract: A method for activating silicone rubber surfaces comprising steps of: i) swelling at least the surface of the silicone rubber matrix with a silicone rubber swelling solvent; ii) treating the silicone rubber matrix during or after the swelling with a solution comprising at least a reactive silane, the reactive silane comprising: a) at least one Si—C bond and; b) at least one hydrolytically labile bond linked to at least one of the Si atoms present in the reactive silane and; c) at least one functional group F1 connected via a Si—C bond to the same or an other Si atom present in the reactive silane, the functional group comprising electrophilic and/or nucleophilic moieties, and/or at least one functional group F2 connected via a Si—C bond to the same or an other Si atom present in the reactive silane comprising moieties which become electrophilic or nucleophilic moieties by a mechanism selected from the group consisting of ring opening of a cyclic structure, hydrolysis, displacement or by a migration reaction;